NASDAQHealth CareMedical - Healthcare Information ServicesSnapshot 2026-08-31
Reading OMDA? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Health Care is in expansion. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar under pressure — Increase Adjusted EBITDA to $14M-$20M in 2026: FY26 EBITDA guidance $21M-$27M vs $14M-$20M target.
View ThesisMiddle-of-the-pack management execution.
View ManagementExpectations look high — the market is pricing in about 63% growth a year, above the roughly 23% analysts expect, leaving little room for error.
View ValuationThis stock is volatile — it swings about 2% on a typical day and fell roughly 59% in its worst 12-month stretch.
View RiskOmada Health's growth strategy relies on achieving 30% revenue growth in 2026. Recent performance shows strong revenue growth, with a 43% increase year over year. It trades at 74× P/E, which is 2.9× the peer median of 25.4. The market expects more growth than the company forecasts, indicating full expectations. A specific risk is the potential for a credibility hit if guidance is cut. Peer multiples imply a price about 57% below where it trades. This read is provisional.
Trailing returns as of 2026-08-31. OMDA is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 12 analysts currently covering OMDA (as of Aug 2026).
Based on 8 Wall Street analysts offering 12-month price targets for OMDA in the last 4 months.
A consensus fair price across 10 valuation methods, at three horizons. As of 2026-08-31. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Health Care Technology — fair value, gap to price, and forward P/E.
Advances: Increase Adjusted EBITDA to $21M-$27M in 2026
Q2 growth supports EBITDA target for 2026.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-08-31. EPS is implied from price ÷ P/E. Not investment advice.
Current $24.55
The last 12 months of price, then the range of analyst 12-month targets from today’s $24.55.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Below average on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Advances: Achieve 30% revenue growth in 2026
Record Q2 supports revenue growth target for 2026.
Advances: Expand total members and commercial channels
Discussion on channel reach aligns with member expansion goals.
Lack of pricing power could hinder revenue growth.
